+Compare
BNTX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
25.52B

BNTX Price Prediction, BioNTech SE American Depositary Share AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for BNTX with price predictions
08:00 PM EDT Sep 21, 2023

BNTX in downward trend: 10-day moving average broke below 50-day moving average on September 22, 2023

The 10-day moving average for BNTX crossed bearishly below the 50-day moving average on September 22, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 12, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on BNTX as a result. In of 68 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BNTX turned negative on September 08, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .

BNTX moved below its 50-day moving average on September 18, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTX advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

BNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 177 cases where BNTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.200) is normal, around the industry mean (22.655). P/E Ratio (5.513) is within average values for comparable stocks, (131.527). Projected Growth (PEG Ratio) (0.046) is also within normal values, averaging (3.920). Dividend Yield (0.013) settles around the average of (0.034) among similar stocks. P/S Ratio (2.627) is also within normal values, averaging (308.747).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I. Advisor
published Earnings

BNTX is expected to report earnings to fall 211.58% to 88 cents per share on November 06

BioNTech SE American Depositary Share BNTX Stock Earnings Reports
Q3'23
Est.
$0.88
Q2'23
Beat
by $0.04
Q1'23
Beat
by $1.78
Q4'22
Beat
by $1.14
Q3'22
Beat
by $3.35
The last earnings report on August 07 showed earnings per share of -79 cents, beating the estimate of -82 cents. With 470.17K shares outstanding, the current market capitalization sits at 25.52B.
A.I.Advisor
published Dividends

BNTX paid dividends on June 17, 2022

BioNTech SE American Depositary Share BNTX Stock Dividends
А dividend of $4.22 per share was paid with a record date of June 17, 2022, and an ex-dividend date of June 02, 2022. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 410.6B. NVO holds the highest valuation in this group at 410.6B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was 32%, and the average quarterly price growth was 32%. SKYED experienced the highest price growth at 81%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
An der Goldgrube 12
Phone
+49 613190840
Employees
4530
Web
https://www.biontech.de
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MRTX41.004.50
+12.33%
Mirati Therapeutics
SMLP13.450.22
+1.66%
Summit Midstream Partners LP
HBAN10.31-0.08
-0.77%
Huntington Bancshares
CLSK3.93-0.13
-3.20%
CleanSpark
CREG1.27-0.14
-9.91%
Smart Powerr Corp

BNTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTX has been closely correlated with MRNA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if BNTX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTX
1D Price
Change %
BNTX100%
-1.68%
MRNA - BNTX
75%
Closely correlated
-0.24%
AXON - BNTX
43%
Loosely correlated
-0.36%
SRNEQ - BNTX
37%
Loosely correlated
-2.54%
FGEN - BNTX
33%
Loosely correlated
-6.50%
GMAB - BNTX
33%
Poorly correlated
-1.12%
More